University of Patras
Αναδρομική μελέτη για τον καθορισμό ομάδας φαρμακογονιδιωματικών βιοδεικτών με σκοπό τον προσδιορισμό της δοσολογίας της τακρολίμης για την εξατομίκευση της θεραπείας μεταμοσχευμένων ασθενών
Abstract
dc:descriptionTacrolimus is a cornerstone calcineurin inhibitor in immunosuppressive therapy following kidney transplantation, due to its high efficacy in preventing acute rejection and improving long-term graft survival. However, its clinical use is complicated by a narrow therapeutic window and pronounced pharmacokinetic variability, making dose optimization particularly challenging. Initial dosing is empirically based on body weight and subsequently adjusted through therapeutic drug monitoring of blood concentrations. This approach often results in under- or overexposure, especially during the early post-transplant period, thereby increasing the risk of acute rejection or drug-related toxicity, such as nephrotoxicity. Tacrolimus is primarily metabolized by the CYP3A4 and CYP3A5 enzymes. Genetic polymorphisms in the CYP3A5 significantly influence dose requirements, with CYP3A5 expressers requiring higher doses than non-expressers. Although current clinical guidelines recommend CYP3A5 genotyping, its clinical benefit remains uncertain. In addition, genetic variants in CYP3A4 and ABCB1 genes may further contribute to pharmacokinetic variability, although available evidence is limited. In this retrospective study, we evaluated the impact of combined CYP3A phenotypes on tacrolimus dose requirements and drug exposure in 94 Greek kidney transplant recipients, from treatment initiation up to one year post-transplantation. Patients were classified into four phenotypic groups based on the combined functional effects of CYP3A4 and CYP3A5. Moreover, the influence of transplant type, sex, age, and ABCB1 haplotypes on tacrolimus pharmacokinetics was evaluated. CYP3A5 expressers with increased CYP3A4 activity consistently exhibited lower dose-adjusted tacrolimus concentrations, indicating faster drug metabolism and higher dose requirements throughout the first post-transplant year. In contrast, no statistically significant effect of ABCB1 genetic variants on tacrolimus pharmacokinetics was observed. Recipients of kidneys from living donors required lower dose requirements during the first month after kidney transplantation, whereas sex and age did not appear to substantially affect therapeutic response. In conclusion, stratifying patients according to combined CYP3A pharmacogenomic phenotypes may represent a useful approach for tacrolimus dose optimization and improved immunosuppressive treatment in kidney transplantation.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsironi, Anna
- Τσιρώνη, Άννα
Subjects
dc:subject × 23- Μεταμόσχευση
- Μεταμόσχευση νεφρού
- Φαρμακογονιδιωματική
- Φαρμακογενετική
- Τακρολίμη
- Ανοσοκατασταλτική θεραπεία
- Αναστολέας καλσινευρίνης
- CYP450
- Αντλία εκροής ABCB1
- Transplantation
- Kidney transplantation
- Pharmacogenetics
- Pharmacogenomics
- Tacrolimus
- Immunosuppressive therapy
- Calcineurin inhibitor
- Efflux pump ABCB1
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Health Sciences
- Medical and Health Sciences
- Health sciences, miscellaneous
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60713